Read this expert commentary to gain insights into the rationale and latest clinical evidence for combination strategies with EGFR TKIs for the first-line treatment of EGFR-mutated advanced NSCLC.
What I want my colleagues to know about treating patients with advanced NSCLC and uncommon EGFR mutations, including future directions targeting these mutations.
In this commentary, a lung cancer expert highlights advances from ASCO 2022 in the management of EGFR-mutated NSCLC with acquired resistance to first-line EGFR TKI therapy using rational combination regimens composed of third-generation EGFR TKIs, EGFR monoclonal antibodies, bispecific antibodies, and antibody–drug conjugates.
Adjuvant osimertinib has been approved for the treatment of patients with resectable early-stage EGFR-positive NSCLC for 2 years. A lung cancer expert discusses the continued DFS benefit and lack of OS data to date and reviews considerations for using adjuvant osimertinib in the clinic.
Review this slideset from a workshop series on optimal management of EGFR-mutated advanced NSCLC, including expert insights on promising investigational agents and combination therapy.
In this module, 5 lung cancer experts review oncology healthcare professional survey results on key educational needs for the multidisciplinary oncology team caring for patients with EGFR-mutated NSCLC, including discussion of standard-of-care practices, the latest clinical data, and ongoing challenges.
Downloadable slides capturing key data on standard-of-care practices and ongoing challenges for the multidisciplinary oncology team caring for patients with EGFR-mutated NSCLC as identified by 5 lung cancer experts.
Review an expert’s perspective on novel combination therapies and antibody–drug conjugates for the treatment of patients with EGFR-mutated advanced NSCLC in the first-line setting and beyond, including emerging data and key ongoing trials.
Download these slides for emerging data and a summary of key ongoing clinical trials evaluating novel combination therapies and antibody–drug conjugates for patients with EGFR-mutated advanced NSCLC in the first-line setting and beyond.
Download this focused resource for a quick guide to EGFR-targeted agents used in current practice for patients with advanced NSCLC and EGFR mutations, including exon 20 insertions.
Download this clinical resource for expert recommendations from May 2022 on molecular testing for targetable genetic alterations in patients with advanced NSCLC.
Download this short resource for a summary of ongoing clinical trials and active areas of research in the setting of EGFR-mutated NSCLC.
Watch this on-demand webcast capturing a dynamic workshop led by an expert on managing EGFR-mutated NSCLC, including guidance on biomarker testing, treatment selection in the setting of early-stage and advanced disease, and future directions to improve outcomes for these patients
Listen to experts answer questions from a live meeting series on optimizing the care of patients with EGFR-mutated non-small-cell lung cancer in the clinic today.
For further information concerning Lilly grant funding, visit www.lillygrantoffice.com.